News

A Scripps Research team has captured the first high-resolution structural images of human Argonaute 2 in its cutting-ready state, revealing why some small interfering RNA (siRNA) molecules work better than others and how to design more effective ones for this emerging therapy.

Scripps Research discovery finds that restoring the naturally occurring compound erucamide in the eye stabilized tissue in preclinical models of retinal degeneration.

Immunologists at Scripps Research show how a new, experimental drug revives immune cells to fight cancer.

A new program aims to replace a daily HBV drug with once-monthly—or even quarterly—injections for people managing both HIV and HBV.

The Baxter Foundation annually support early-career researchers whose work in science and technology holds promise for improving patient care.

Scripps Research scientists developed a vaccine that teaches the immune system to rapidly neutralize fentanyl and new emerging synthetic fentanyl analogs.

Scripps Research team develops stereoretentive radical-radical cross-coupling, a simpler way to build chiral drug candidates.

CLF065, a long-acting, once-weekly GLP-2 receptor agonist, advances in two inflammatory bowel disease indications. The studies aim to bring a regenerative treatment option to patients living with IBD, who currently have few therapies that repair the damaged intestinal lining at the root of their disease.

In a first for the field, all non-human primates given a new series of vaccines generated antibodies capable of fighting multiple strains of HIV.

Yu is honored by the U.K.’s national academy of sciences for his work in synthetic organic chemistry.

Keren Lasker to be inaugural chair holder

Scripps Research team maps how chemical modifications to proteins affect drug binding across the human proteome.

A leader in broadly neutralizing antibodies, Burton has helped drive global efforts to develop vaccines for HIV, influenza and more.

NULL

Yu is recognized for his pioneering work in synthetic organic chemistry.

Scripps Research scientists discovered that a chemically modified protein puts the brain’s immune cells in a state of damaging, chronic overactivation—and that blocking it protects brain cell connections.

Scripps Research scientists and colleagues develop a nanodisc platform that offers a clearer view of how key viral proteins interact with antibodies.

Funding will expand methods for studying viral proteins and immune responses in more realistic settings for HIV and other severe pathogens.

Scripps Research chemists solve a longstanding problem in the construction of branched molecular frameworks, unlocking a faster path to the complex structures found in drugs and materials.

The doctoral program also placed #7 in Chemistry in the publication’s latest issue ranking top science graduate schools.

Discovery reshapes understanding of how tumor cells repair broken DNA, pointing toward more precise cancer therapies.

First-in-class molecules block a specific protein interaction in immune cells, offering a potential targeted approach to autoimmune diseases like lupus and rheumatoid arthritis.